Drug Distribution and Excretion Analysis with LC-MS/MS

In preclinical drug development, particularly during lead candidate optimization and non-clinical safety assessment, drug distribution and excretion (D&E) analysis is critical for understanding the pharmacokinetic behavior of novel compounds. It involves quantifying drug concentrations in biological matrices (e.g., plasma, tissue homogenates, urine, bile, feces) over time to elucidate absorption, distribution, metabolism, and excretion (ADME) profiles. As the gold-standard analytical technique for trace-level quantitative analysis, Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) enables high sensitivity, high specificity, and high-throughput quantification, making it indispensable for supporting IND enabling studies and clinical trial design.

As a professional pharmaceutical CRO institution, PharmaAnalytica provides comprehensive, GLP-compliant Drug Distribution and Excretion Analysis Services powered by LC-MS/MS. Our service is tailored for small-molecule drug candidates and lead compounds, leveraging state-of-the-art instrumentation and validated methodologies to deliver accurate, reproducible, and regulatory-ready D&E data. We support both tissue distribution studies (to map biodistribution) and excretion analysis (to quantify recovery in urine, bile, and feces), providing critical insights into drug clearance pathways and potential toxicity risks.

Core Test Content We Provide

1. LC-MS/MS Bioanalytical Method Support
   • Custom MRM transition optimization and full LC-MS/MS method development for your lead compound.
   • Complete method validation following ICH Q2(R1): precision, accuracy, matrix effect, recovery, stability and LOQ/LOD confirmation.
   • Sample pre-treatment: protein precipitation, LLE, SPE automatic purification for complex biological matrices.
   • Batch high-throughput testing for large preclinical study sample batches.
2. Tissue Distribution Analysis Service
   • Whole-animal tissue distribution profiling in rodents (mice/rats) and large animals (dogs): liver, kidney, brain, heart, lung, spleen, muscle, fat, plasma and more than 20 major organs.
   • Time-point concentration detection after administration (multiple sampling time series) to draw tissue concentration–time curves.
   • Comparison of distribution differences between normal and damaged tissues for safety risk assessment.
   • Targeted blood–brain barrier penetration testing to evaluate CNS drug delivery potential.
3. Excretion Pathway & Mass Balance Analysis
   • Cumulative drug determination in urine, feces and bile samples to clarify main excretion routes.
   • Calculation of total dose recovery rate and completion of full mass balance research.
   • Differentiate quantification of prototype drug and metabolites in excreta by LC-MS/MS.
   • Long-term dynamic excretion monitoring to characterize elimination half-life and clearance features.

PharmaAnalytica delivers comprehensive, regulatory-compliant Drug Distribution and Excretion Analysis reports, including: Detailed study protocols and SOPs (GLP-aligned).

• Raw LC-MS/MS data, chromatograms, and MRM transitions.
• Quantitative concentration-time profiles for tissue and excretion samples.
• Biodistribution maps and cumulative excretion percentages.
• Mass balance summary and metabolite identification results.
• Pharmacokinetic parameter calculations.
• Expert analysis and recommendations for lead candidate selection and safety assessment.

All data is fully compliant with ICH M4, ICH Q2(R1), FDA Guidance for Industry: Bioanalytical Method Validation, and EMA guidelines, making it suitable for preclinical IND enabling studies, clinical trial design, and non-clinical safety evaluation.

PharmaAnalytica's Technology Platform

PharmaAnalytica's Service Advantages

GLP-Compliant Validated Methods

All LC-MS/MS assays are fully validated according to ICH Q2(R1) and FDA bioanalytical guidelines, including accuracy, precision, sensitivity, specificity, and matrix effect evaluation.

Expert Scientific Support

Our team of experienced pharmacologists and bioanalysts provides in-depth data interpretation, pharmacokinetic modeling, and actionable recommendations for lead optimization.

High-Throughput & Fast Turnaround

Automated sample preparation and fast LC-MS/MS workflows reduce analysis time, enabling rapid lead candidate evaluation and project progression.

Regulatory-Ready Deliverables

Generate complete, traceable D&D study reports including raw data, chromatograms, method validation records, and statistical analysis, directly supporting IND and NDA submissions.

For successful preclinical drug development, accurate, sensitive, and reproducible drug distribution and excretion analysis is essential to mitigate safety risks and optimize lead candidates. PharmaAnalytica's Drug Distribution and Excretion Analysis with LC-MS/MS service combines state-of-the-art instrumentation, validated GLP workflows, and expert scientific support to deliver high-quality D&E data. We help clients accelerate lead optimization, complete IND-enabling studies, and support clinical development, ensuring the safe and efficient progression of drug candidates to market.